Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perfusion CT as a biomarker in phase II apatinib basket study for progressed solid tumors after second-line treatment failure
ChiCTR1900021799Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in Nonhematologic neoplasms, sponsored by Ruijin Hospital. Primary endpoint: progression-free survival. Started Mar 2019; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR1900021799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021799.